Page last updated: 2024-08-21

arsenic trioxide and Cutaneous T-Cell Lymphoma

arsenic trioxide has been researched along with Cutaneous T-Cell Lymphoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Assaf, C; Beyer, M; Cosagarea, I; Möbs, M; Touba, R; Vandersee, S	1
Bachelez, H; Degos, L; Dombret, H; Dubertret, L; Dupuy, A; Jean-Louis, F; Michel, L; Musette, P; Poupon, J; Sors, A; Viguier, M	1
Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA	1

Trials

1 trial(s) available for arsenic trioxide and Cutaneous T-Cell Lymphoma

Article	Year
Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). The Journal of investigative dermatology, 2003, Volume: 121, Issue:4 Topics: Aged; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Division; Cell Line, Tumor; Clone Cells; Drug Synergism; Humans; Leukocytes, Mononuclear; Lymphoma, T-Cell, Cutaneous; Middle Aged; Mitochondria; Oxides; Skin Neoplasms	2003

Article

Year

Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C).

The Journal of investigative dermatology, 2003, Volume: 121, Issue:4

Topics: Aged; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Division; Cell Line, Tumor; Clone Cells; Drug Synergism; Humans; Leukocytes, Mononuclear; Lymphoma, T-Cell, Cutaneous; Middle Aged; Mitochondria; Oxides; Skin Neoplasms

2003

Other Studies

2 other study(ies) available for arsenic trioxide and Cutaneous T-Cell Lymphoma

Article	Year
The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines. Skin pharmacology and physiology, 2016, Volume: 29, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Lymphoma, T-Cell, Cutaneous; Oxides; Tretinoin	2016
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. The oncologist, 2001, Volume: 6, Issue:1 Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration	2001

Article

Year

The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines.

Skin pharmacology and physiology, 2016, Volume: 29, Issue:2

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Lymphoma, T-Cell, Cutaneous; Oxides; Tretinoin

2016

Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.

The oncologist, 2001, Volume: 6, Issue:1

Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration

2001